Stanford University
Showing 1-10 of 27 Results
-
C. Andrew Bonham, MD, FACS
Associate Professor of Surgery (Abdominal Transplantation), Emeritus
Current Research and Scholarly InterestsTolerance induction in liver transplantation.
Hepatocyte transplantation. -
Stephan Busque
Professor of Surgery (Abdominal Transplantation), and by courtesy, of Medicine (Nephrology)
Current Research and Scholarly InterestsMy research interest is focused on the improvement of clinical immunosuppression. I am involved in the evaluation of new immunosuppressive drugs, potentially more efficacious or less toxic. My ultimate goal is to achieve tolerance, a state that would obviate the need for any drugs. I am an investigator part of a multidisciplinary tolerance induction project using total lymphoid irradiation and donor hematopoietic stem cells infusion after living donor kidney transplantation.
-
Xingxing Shelley Cheng
Assistant Professor of Medicine (Nephrology) and, by courtesy, of Surgery (Abdominal Transplantation) and of Health Policy
Current Research and Scholarly InterestsDr. Xingxing Cheng's expertise is in applying the tools of decision science to clinical practice and policy analysis. Her current research is in the following areas:
1) the costs, effectiveness, and implementation of work-up before kidney transplantation, including pretransplant cardiovascular screening;
2) ethics of and decision-making in in multi-organ transplantation. -
Carlos O. Esquivel, M.D., Ph.D.,FACS
Arnold and Barbara Silverman Professor in Pediatric Transplantation and Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Gastroenterology, Hepatology and Nutrition)
Current Research and Scholarly Interests1) Induction of immunotolerance
2) Rejection of liver and intestinal transplantation.
3) Clinical outcomes of children with unresectable liver tumors. -
Daniel James Firl
Clinical Instructor, Surgery - Abdominal Transplantation
BioDaniel Firl is an abdominal transplant surgery fellow at Stanford Medicine and a surgeon-scientist working at the intersection of hepatobiliary cancer surgery and transplantation. His work centers on patient selection in primary liver cancer — determining which patients are best served by resection and which by transplantation — and on the risk-assessment tools that make that decision more precise.
He is a co-developer of HALT-HCC, a risk model for liver transplantation in hepatocellular carcinoma, and first author of its international validation across more than 4,000 patients. His aim is to make selection between resection and transplantation progressively more sophisticated — sharpening prediction of waitlist and post-transplant outcomes, informing donor selection, and enabling the safe use of grafts that might otherwise be declined — with a particular interest in intrahepatic cholangiocarcinoma and gallbladder cancer, where the role of transplantation is still being defined. He sees the next step as the integration of tumor genomics, bringing the molecular features of each cancer into the models that guide surgical decisions.
Earlier, during postdoctoral training at the Massachusetts General Hospital, he studied the immunology and physiology of kidney xenotransplantation, including the design and long-term function of organs from genetically engineered porcine donors — part of the broader effort to expand the supply of transplantable organs.
Dr. Firl completed general surgery residency at Duke University, where he served as chief resident, and earned his MD with Special Qualifications in Biomedical Research through the research-intensive program at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds a bachelor's degree in biochemistry from Boston College.
He is the author of over 30 peer-reviewed articles, with work in Nature, Cell, The Lancet Gastroenterology & Hepatology, Hepatology, and The Lancet Digital Health. He serves as an ad hoc reviewer for journals including The BMJ, Kidney International, the American Journal of Transplantation, JCO Precision Oncology, and Transplantation.
He has received fellowships and grant funding from prestigious organizations during competitive funding opportunities including from: the NIH-NIAID, Howard Hughes Medical Institute, and the American Society of Transplantation.
